Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingSep 10, 2025chlorproMAZINE Hydrochloride TabletsPresence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism...Amneal Pharmaceuticals, LLC · D-0616-2025Class IIOngoingSep 10, 2025Sulfamethoxazole and Trimethoprim TabletsPresence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism...Amneal Pharmaceuticals, LLC · D-0615-2025Class IIOngoingSep 10, 2025KIMMTRAKSubpotent DrugImmunocore, LLC · D-0614-2025Class IOngoingSep 10, 2025PeriGieneMicrobial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.DermaRite Industries, LLC · D-0613-2025Class IOngoingSep 10, 2025KleenFoamMicrobial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.DermaRite Industries, LLC · D-0612-2025Class IOngoingSep 10, 2025DermaSarraMicrobial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.DermaRite Industries, LLC · D-0611-2025Class IOngoingSep 10, 2025DermaKleenMicrobial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.DermaRite Industries, LLC · D-0610-2025Class IIOngoingSep 10, 2025SemaglutideSubpotent DrugBoothwyn Pharmacy LLC · D-0609-2025Class IIOngoingSep 10, 2025SemaglutideSubpotent DrugBoothwyn Pharmacy LLC · D-0608-2025Class IIIOngoingSep 10, 2025Fluorescein 2% OphthSubpotent DrugBoothwyn Pharmacy LLC · D-0607-2025Class IIOngoingSep 10, 2025SemaglutideSubpotent DrugBoothwyn Pharmacy LLC · D-0606-2025Class IIOngoingSep 3, 2025RITE AID PHARMACYSubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0605-2025Class IIOngoingSep 3, 2025Good Neighbor PharmacySubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0604-2025Class IIOngoingSep 3, 2025H-E-B, inControlSubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0603-2025Class IIOngoingSep 3, 2025ReliOn, Sterile Alcohol SwabsSubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0602-2025Class IIOngoingSep 3, 2025CURAD Alcohol Prep PadsSubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0601-2025Class IIOngoingSep 3, 2025Medline Alcohol Prep PadsSubpotent Drug- isopropyl alcohol levels fall below the labeled concentration.MEDLINE INDUSTRIES, LP - Northfield · D-0600-2025Class IITerminatedSep 3, 2025Lisdexamfetamine Dimesylate CapsulesLabeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.Lannett Company Inc. · D-0599-2025Class IIOngoingSep 3, 2025Sucralfate TabletsCGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet...Amerisource Health Services LLC · D-0598-2025Class IIOngoingSep 3, 2025Enoxaparin Sodium InjectionCorrect Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mLCardinal Health Inc. · D-0597-2025Class IIOngoingSep 3, 2025Acetaminophen Injection 1000 mg/100 mLDiscolorationBaxter Healthcare Corporation · D-0596-2025Class IIOngoingAug 27, 2025Tavaborole Topical Solution 5%DiscolorationViona Pharmaceuticals Inc · D-0595-2025Class IIOngoingAug 27, 2025Carvedilol Tablets USPCGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppmThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0594-2025Class IIIOngoingAug 27, 2025Albuterol SulfateFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.Cipla USA, Inc. · D-0593-2025Class IIIOngoingAug 27, 2025Sensodyne PRONAMELLabeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on...Haleon US Holdings LLC · D-0592-2025Class IIOngoingAug 27, 2025Vial Label: 8.4% Sodium Bicarbonate InjectionLack of Assurance of Sterility.Pfizer Inc · D-0591-2025Class IIOngoingAug 27, 2025Vial Label: Epinephrine InjectionLack of Assurance of Sterility.Pfizer Inc · D-0590-2025Class IIOngoingAug 27, 2025BZK Antiseptic ToweletteLack of Assurance of Sterility.Taizhou Kangping Medical Science And Technology Co., Ltd. · D-0589-2025Class IIOngoingAug 20, 2025Carvedilol TabletsCGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppmGlenmark Pharmaceuticals Inc., USA · D-0588-2025Class IIOngoingAug 20, 2025Carvedilol TabletsCGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppmGlenmark Pharmaceuticals Inc., USA · D-0587-2025Class IIOngoingAug 20, 20250.9% Sodium Chloride Injection USPLack of Assurance of Sterility; potential for fluid leakage at one of the weld sites.B Braun Medical Inc · D-0586-2025Class IIOngoingAug 20, 2025Lactated Ringer's Injection USPLack of Assurance of Sterility; potential for fluid leakage at one of the weld sites.B Braun Medical Inc · D-0585-2025Class IIOngoingAug 20, 2025BelsomraFailed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of...Merck & Co. Inc · D-0584-2025Class IIOngoingAug 20, 2025Theophylline extended-release tablets 400mgFailed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life...Glenmark Pharmaceuticals Inc., USA · D-0583-2025Class IIOngoingAug 20, 2025Metoprolol Tartrate TabletsCGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.Westminster Pharmaceuticals LLC · D-0582-2025Class IIOngoingAug 20, 2025Metoprolol Tartrate TabletsCGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.Westminster Pharmaceuticals LLC · D-0581-2025Class IIOngoingAug 20, 2025Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.Breckenridge Pharmaceutical, Inc. · D-0580-2025Class IIOngoingAug 20, 2025Carvedilol TabletsCGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.Glenmark Pharmaceuticals Inc., USA · D-0579-2025Class IIOngoingAug 20, 2025Carvedilol TabletsCGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.Glenmark Pharmaceuticals Inc., USA · D-0578-2025Class IIOngoingAug 20, 2025Carvedilol TabletsCGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.Glenmark Pharmaceuticals Inc., USA · D-0577-2025